Scancell Holdings Plc (SCLP)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Scancell Holdings Plc (SCLP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013630
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Scancell Holdings Plc (Scancell) is a pharmaceutical company that develops, manufactures and markets cancer vaccines. The company develops products that stimulate the immune system to treat or prevent cancer. It offers SCIB1, a cancer vaccine that is used in the treatment of melanoma. Scancell’s product stimulates immune responses to the lung cancer antigen NY-ESO-1. The company’s SCIB2 scancell Immunobody immunotherapy platform enhances the uptake and presentation of cancer antigens to harness T cell responses to destroy tumours. It offers products for treatment of oesophageal, liver, gastric, prostate, ovarian and bladder cancers. The company operates in Nottingham, Manchester, Newcastle, Leeds and Southampton. Scancell is headquartered in Oxford, the UK.

Scancell Holdings Plc (SCLP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Scancell Holdings Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Scancell Holdings Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Scancell Holdings Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Scancell Holdings Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Scancell Holdings Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Scancell Holdings Plc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Addario Lung Cancer Medical Institute Enters into Agreement with Scancell 10
Scancell Holdings Enters into Agreement with Nottingham Trent University and University of Portsmouth 11
Scancell Enters into Research Agreement with Karolinska Institutet 12
Scancell Holdings Forms Partnership with ImmunID 13
Equity Offering 14
Scancell Holdings Raises USD6.5 Million in Private Placement of Shares 14
Scancell Raises USD4 Million in Rights Offering of Shares 15
Scancell Raises USD4.49 Million in Private Placement of Shares 16
Scancell Completes Private Placement Of Shares For US$7 Million 18
Scancell Completes Private Placement Of Shares For US$3 Million 19
Scancell Holdings Plc – Key Competitors 20
Scancell Holdings Plc – Key Employees 21
Scancell Holdings Plc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Sep 13, 2017: Scancell Holdings: Final Results for the year ended 30 April 2017 23
Sep 13, 2017: Scancell Holdings: Final Results for the year ended 30 April 2017 28
Jan 31, 2017: Scancell Holdings Announces Interim Results For The 6 Months Ended 31 October 2016 29
Sep 16, 2016: Scancell Holdings: Final Results for the year ended 30 April 2016 30
Jan 27, 2016: Interim Results for the six months ended 31 October 2015 31
Corporate Communications 34
Oct 10, 2017: Scancell Holdings: Scancell appoints Dr Cliff Holloway as Chief Executive Officer 34
Oct 10, 2017: Scancell appoints Dr Cliff Holloway as Chief Executive Officer 36
Jan 07, 2016: Scancell Holdings announces the appointment of John Chiplin as Non-Executive Chairman 37
Product News 38
10/10/2016: Scancell preparing SCIB2 for clinical study in lung cancer 38
07/13/2016: Publication highlights advantages of Moditope technology platform 39
07/06/2016: SCIB1 continues to deliver compelling survival data in melanoma 40
06/17/2016: SCIB1 Drug Product Supply 41
03/23/2016: Scancell’s SCIB1 ImmunoBody cancer vaccine being presented at the World Vaccine Congress 42
Clinical Trials 43
Jan 11, 2016: Early Immune Effect of SCIB1 Cancer Vaccine Observed in Blood by ImmunTraCkeR® Companion Diagnostic 43
Other Significant Developments 44
Apr 13, 2017: Scancell Holdings: Change of Registered Office 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
Scancell Holdings Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Scancell Holdings Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Scancell Holdings Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Scancell Holdings Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Scancell Holdings Plc, Deals By Therapy Area, 2011 to YTD 2017 8
Scancell Holdings Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Addario Lung Cancer Medical Institute Enters into Agreement with Scancell 10
Scancell Holdings Enters into Agreement with Nottingham Trent University and University of Portsmouth 11
Scancell Enters into Research Agreement with Karolinska Institutet 12
Scancell Holdings Forms Partnership with ImmunID 13
Scancell Holdings Raises USD6.5 Million in Private Placement of Shares 14
Scancell Raises USD4 Million in Rights Offering of Shares 15
Scancell Raises USD4.49 Million in Private Placement of Shares 16
Scancell Completes Private Placement Of Shares For US$7 Million 18
Scancell Completes Private Placement Of Shares For US$3 Million 19
Scancell Holdings Plc, Key Competitors 20
Scancell Holdings Plc, Key Employees 21
Scancell Holdings Plc, Subsidiaries 22

★海外企業調査レポート[Scancell Holdings Plc (SCLP)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Transaero Inc:企業の戦略・SWOT・財務情報
    Transaero Inc - Strategy, SWOT and Corporate Finance Report Summary Transaero Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Mitsui E&S Holdings Co., Ltd. (7003):企業の財務・戦略的SWOT分析
    Mitsui E&S Holdings Co., Ltd. (7003) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Massachusetts General Hospital-医療機器分野:企業M&A・提携分析
    Summary Massachusetts General Hospital (MGH) is a healthcare service provider which offers diagnostic and therapeutic care services. The hospital provides services such as allergy and immunology; ALS multidisciplinary clinic, anesthesia, critical care and pain medicine; back bay healthcare center, b …
  • Abbott Laboratories (ABT)-製薬・医療分野:企業M&A・提携分析
    Summary Abbott Laboratories (Abbott) is a healthcare company, which discovers, develops, manufactures, and sells a diversified range of healthcare products including drugs, diagnostics, branded generics, and vascular and nutritional products. The company’s products comprise specialized medicines; me …
  • Nissin Foods Holdings Co. Ltd:企業の戦略・SWOT・財務情報
    Nissin Foods Holdings Co. Ltd - Strategy, SWOT and Corporate Finance Report Summary Nissin Foods Holdings Co. Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Macquarie Group Ltd:企業の戦略・SWOT・財務分析
    Macquarie Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Macquarie Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Repsol SA (REP):企業の財務・戦略的SWOT分析
    Repsol SA (REP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • transcosmos Inc:企業の戦略・SWOT・財務分析
    transcosmos Inc - Strategy, SWOT and Corporate Finance Report Summary transcosmos Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Las Vegas Sands Corp:企業の戦略・SWOT・財務情報
    Las Vegas Sands Corp - Strategy, SWOT and Corporate Finance Report Summary Las Vegas Sands Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Cornerstone OnDemand, Inc.:企業のM&A・事業提携・投資動向
    Cornerstone OnDemand, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Cornerstone OnDemand, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Screen Holdings Co., Ltd. (7735):企業の財務・戦略的SWOT分析
    Screen Holdings Co., Ltd. (7735) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Ben E. Keith Co:企業の戦略的SWOT分析
    Ben E. Keith Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Freeport-McMoRan Inc:企業の戦略・SWOT・財務情報
    Freeport-McMoRan Inc - Strategy, SWOT and Corporate Finance Report Summary Freeport-McMoRan Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Qatar Islamic Bank
    Qatar Islamic Bank - Strategy, SWOT and Corporate Finance Report Summary Qatar Islamic Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • MicroStrategy Inc (MSTR):企業の財務・戦略的SWOT分析
    MicroStrategy Inc (MSTR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • OneMain Holdings Inc:企業の戦略・SWOT・財務分析
    OneMain Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary OneMain Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Orange Polska S.A.:戦略・SWOT・企業財務分析
    Orange Polska S.A. - Strategy, SWOT and Corporate Finance Report Summary Orange Polska S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Mindteck (India) Limited:戦略・SWOT・企業財務分析
    Mindteck (India) Limited - Strategy, SWOT and Corporate Finance Report Summary Mindteck (India) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Hecla Mining Company:企業の戦略・SWOT・財務分析
    Hecla Mining Company - Strategy, SWOT and Corporate Finance Report Summary Hecla Mining Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • China National Pharmaceutical Group Corp-製薬・医療分野:企業M&A・提携分析
    Summary China National Pharmaceutical Group Corp (Sinopharm) is a provider of medical and healthcare services. Its core businesses include the distribution, retailing, research and manufacture of healthcare related products. Its product portfolio includes EPI vaccines; biopharmaceutical products; an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆